Alterations in methotrexate pharmacokinetics by naproxen in the rat as measured by microdialysis

Life Sciences

Volumn 60, Issue 24, 1997, Pages PL359-PL364

  Ekstrøm, Per Olaf ^a   Giercksky, Karl E ^a   Andersen, Anders ^a   Sloørdal, Lars ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b National Institute of Forensic Toxicology   (Norway)

Author keywords

7 hydroxymethotrexate; methotrexate; microdialysis; naproxen; Wistar rat

Indexed keywords

7 HYDROXYMETHOTREXATE; METHOTREXATE; NAPROXEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; DRUG PROTEIN BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MALE; MICRODIALYSIS; NONHUMAN; RAT;

EID: 0343035752     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00241-5     Document Type: Article

References (30)

1. W.A. BLEYER, Cancer 4136-51 (1978).
2. J. JOLIVET, K.H. COWAN, G.A. CURT, N.J. CLENDENINN and B.A. CHABNER, N Engl J Med 309 1094-104 (1983).
3. C.J. MCDONALD, J Am Acad Dermatol 12 753 (1985).
4. M.C. CREEMERS, M.J. FRANSSEN, L.B. VAN-DE PUTTE, F.W. GRIBNAU and P.L. VAN-RIEL, J Rheumatol 22 1104-7 (1995).
5. W.S. WILKE and A.H. MACKENZIE, Drugs 32 103-13 (1986).
6. J.M. KREMER, G.F. PETRILLO and R.A. HAMILTON, J Rheumatol 22 38-40 (1995).
7. A.G. JOHNSON, P. SEIDEMANN and R.O. DAY, Int J Clin Pharmacol Ther 32 509-32 (1994).
8. E.P. BRASS, Cleve Clin J Med 60 466-72 (1993).
9. M.L. FRENIA and K.S. LONG, Ann Pharmacother 26 234-7 (1992).
10. D.M. CLIVE and J.S. STOFF, N Engl J Med 310 563-72 (1984).
11. L. SLØRDAL, G. SAGER and J. AARBAKKE, Lancet 1 591-2 (1988).
12. Anonymous, Lancet 339 1326-7 (1992).
13. B. BLÖCHL-DAUM, M. MÜLLER, V. MEISINGER, H.G. EICHLER, A. FASSOLT and H. PEHAMBERGER, Br J Cancer 73 920-4 (1996).
14. U. UNGERSTEDT, J Intern Med 230 365-73 (1991).
15. P.O. EKSTRØM, A. ANDERSEN, G. SÆTER, K.E. GIERCKSKY and L. SLØRDAL, Cancer Chemother Pharmacol 39 267-272 (1997).
16. R.K. PALSMEIER and C.E. LUNTE, Life Sci 55 815-25 (1994).
17. P.O. EKSTRØM, A. ANDERSEN, D.J. WARREN, K.E. GIERCKSKY and L. SLØRDAL, Cancer Chemother Pharmacol 34 297-301 (1994).
18. P.O. EKSTRØM, A. ANDERSEN, D.J. WARREN, K.E. GIERCKSKY and L. SLØRDAL, Cancer Chemother Pharmacol 32 394-400 (1996).
19. P.O. EKSTRØM, A. ANDERSEN, D.J. WARREN, K.E. GIERCKSKY and L. SLØRDAL, Cancer Chemother Pharmacol 36 283-289 (1995).
20. R.M. BREMNES, L. SLØRDAL, E. WIST and J. AARBAKKE, Cancer Res 49 2460-4 (1989).
21. R.M. BREMNES, E. SMELAND, N.E. HUSEBY, T.J. EIDE and J. AARBAKKE, Pharmacol Toxicol 69 132-9 (1991).
22. R.M. BREMNES, L. SLØRDAL, E. WIST and J. AARBAKKE, Cancer Res 49 6359-64 (1989)
23. L. SLØRDAL, P.S. PRYTZ, I. PETTERSEN and J. AARBAKKE, Ther Drug Monit 8 368-372 (1986).
24. L. SLØRDAL, G. SAGER, R. JÆGER and J. AARBAKKE, Biochem Pharmacol 37 607-11 (1988).
25. J.W. PAXTON, J Pharmacol Methods 5 203-13 (1981).
26. J.W. PAXTON, Clin Exp Pharmacol Physiol 2 225-34 (1982).
27. L. DETTLI, Pharmacokinetic aspects of drug interactions., L. E. Cluff and J. C. Petrie (Eds), 39-68, Publishe, New York (1974).
28. E. SMELAND, O.M. FUSKEVAG, K. NYMANN, J.S. SVENDESN, R. OLSEN, S. LINDAL, R.M. BREMNES and J. AARBAKKE, Cancer Chemother Pharmacol 37 415-22 (1996).
29. E. SMELAND, R.M. BREMNES, A. ANDERSEN, R. JÆGER, T.J. EIDE, N.E. HUSEBY and J. AARBAKKE, Cancer Chemother Pharmacol 34 119-24 (1994).
30. S.A. JACOBS, R.G. STOLLER, B.A. CHABNER and D.G. JOHNS, J Clin Invest 57 534-8 (1976).